Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALV 
Kalvista Pharmaceuticals Inc (KALV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: KALV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.67
1 Year Target Price $31.67
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.85% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 682.06M USD | Price to earnings Ratio - | 1Y Target Price 31.67 |
Price to earnings Ratio - | 1Y Target Price 31.67 | ||
Volume (30-day avg) 10 | Beta -0.1 | 52 Weeks Range 7.30 - 17.28 | Updated Date 09/17/2025 |
52 Weeks Range 7.30 - 17.28 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.94 |
Earnings Date
Report Date 2025-09-03 | When Before Market | Estimate -0.9 | Actual -1.12 |
Profitability
Profit Margin - | Operating Margin (TTM) -4138.08% |
Management Effectiveness
Return on Assets (TTM) -60.98% | Return on Equity (TTM) -190.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 496740199 | Price to Sales(TTM) 478.31 |
Enterprise Value 496740199 | Price to Sales(TTM) 478.31 | ||
Enterprise Value to Revenue 348.35 | Enterprise Value to EBITDA -3.53 | Shares Outstanding 50523300 | Shares Floating 28310211 |
Shares Outstanding 50523300 | Shares Floating 28310211 | ||
Percent Insiders 1.3 | Percent Institutions 111.57 |
Upturn AI SWOT
Kalvista Pharmaceuticals Inc
Company Overview
History and Background
Kalvista Pharmaceuticals Inc. is a pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors to treat diseases with significant unmet needs. Founded in 2010, it has focused primarily on hereditary angioedema (HAE) and diabetic macular edema (DME).
Core Business Areas
- Hereditary Angioedema (HAE): Development of oral therapies for on-demand and prophylactic treatment of HAE attacks.
- Early Stage Research: Discovery and preclinical research programs targeting other kallikrein-related indications.
Leadership and Structure
The leadership team includes executives with expertise in drug development and commercialization. The organizational structure is typical of a biotech company, with departments focused on research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Sebetralstat (Oral HAE On-Demand Treatment): A novel oral plasma kallikrein inhibitor for on-demand treatment of HAE attacks. Kalvista halted development of sebetralstat following adverse events in a Phase 3 trial. Shire (now Takeda) with Takhzyro and BioCryst Pharmaceuticals with Orladeyo are competitors.
- KVD824 (Oral HAE Prophylactic Treatment): An oral plasma kallikrein inhibitor for prophylactic treatment of HAE attacks. Kalvista has deprioritized its internal HAE franchise. Takeda (Takhzyro), CSL Behring (Haegarda) and BioCryst Pharmaceuticals (Orladeyo) are competitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The HAE market is competitive, with established therapies and emerging oral treatments.
Positioning
Kalvista aimed to compete in the HAE market with oral therapies, offering a potential convenience advantage over injectable treatments. However, with the halting of trials, its positioning has been significantly weakened.
Total Addressable Market (TAM)
The HAE market is estimated to be worth several billion USD annually. Kalvista's opportunity depends on clinical success and market access, which are now limited by the failed trial.
Upturn SWOT Analysis
Strengths
- Strong expertise in kallikrein inhibition
- Focused drug development programs
Weaknesses
- High dependence on single clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial failure of sebetralstat significantly impacts near-term prospects.
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other kallikrein-related indications
- Potential for licensing or selling existing assets.
Threats
- Clinical trial failures
- Competition from established HAE therapies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- TAK
- BCRX
- CSL
Competitive Landscape
Kalvista faces significant competition from established pharmaceutical companies with approved HAE therapies. The oral route of administration was a potential advantage, but clinical trial failures present challenges.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on clinical trial progress and partnering opportunities. Recent clinical trial failure has hindered growth.
Future Projections: Future growth is highly uncertain and dependent on successful partnering or asset sales.
Recent Initiatives: Focusing on advancing early-stage programs and exploring strategic alternatives.
Summary
Kalvista Pharmaceuticals faces significant challenges after the halting of sebetralstat development. The company is exploring strategic alternatives and focusing on early-stage programs. Clinical trial setbacks have significantly weakened its competitive position. Partnerships or asset sales will be critical for the company's future survival and growth. Further research is needed to improve it's fundamental strength.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company-specific events may impact future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kalvista Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-04-09 | CEO & Director Mr. Benjamin L. Palleiko | ||
Sector Healthcare | Industry Biotechnology | Full time employees 270 | Website https://www.kalvista.com |
Full time employees 270 | Website https://www.kalvista.com | ||
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.